Carteolol, an ophthalmic β-adrenergic blocker with intrinsic sympathomimetic activity

Journal of Glaucoma

Volumn 3, Issue 4, 1994, Pages 339-345

  Stewart, William C ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARTEOLOL; LIPID; LIPOPROTEIN; TIMOLOL;

AMNESIA; ANXIETY; BRADYCARDIA; CONVULSION; DRUG EFFICACY; DRUG TOLERANCE; DYSPNEA; EYE IRRITATION; GLAUCOMA; HEADACHE; HEARING IMPAIRMENT; HUMAN; HYPEREMIA; INTRAOCULAR PRESSURE; INTRINSIC SYMPATHOMIMETIC ACTIVITY; LACRIMATION; LIPID METABOLISM; PERFUSION; PRIORITY JOURNAL; PRURITUS; REVIEW; RHINITIS; SINUSITIS; TASTE DISORDER; TOPICAL DRUG ADMINISTRATION; VERTIGO; VISUAL DISORDER;

EID: 0028598838     PISSN: 10570829     EISSN: 1536481X     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Lesar TS. Comparison of ophthalmic β-blocking agents. Clin Pharm 1987;6:451-63.
2. Nelson WL, Fraunfelder FT, Sills JM, Arrowsmith JB, Kuritsky JN. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985. Am J Ophthalmol 1986;102:606-11.
3. Anand KB, Eschmann E. Systemic effects of ophthalmic medication in the elderly. NY State J Med 1988;88:134-6.
4. Lynch MG, Whitson JT, Brown RH, Nguyen H, Drake MM. Topical β-blocker therapy and central nervous system side effects. A preliminary study comparing betaxolol and timolol. Arch Ophthalmol 1988;106:908-11.
5. Brooks AMV, Gillies WE. Ocular β-blockers in glaucoma management. Drugs Aging 1992;2:208-21.
6. Chrisp P, Sorkin EM. Ocular carteolol. A review of its pharmacological properties, and therapeutic use in glaucoma and ocular hypertension. Drugs Aging 1992;2:58-77.
7. Duff GR. A double-masked crossover study comparing the effects of carteolol \1% and 2% on intra-ocular pressure. Acta Ophthalmol 1987;65:618-21.
8. Collignon-Brach J. Early visual field changes with betablocking agents [Summary]. Surv Ophthalmol 1989;33 (suppl):429-30.
9. Schnaudigel O-E, Becker H, Fuchs H-B. Carteolol: Praxisgerechte prüfung von Wirksamkeit und Verträglichkeit eines neuen betablockers in der behandlung des glaukoms. Klin Monatsbl Augenheilk 1988;192:248-51.
10. Scoville B, Krieglstein GK, Then E, Yokoyama S, Yokoyama T. Measuring drug-induced eye irritation: a simple new clinical assay. J Clin Pharmacol 1985;25:210-18.
11. Flury H, Tournoux A, Martenet AC. Verträglichkeit und pharmacokologische Wirksamkeit von antiglaukomatösen augentropfen. Klin Monatsbl Augenheilk 1986;188:573-5.
12. Scoville B, Mueller B, White BG, Krieglstein GK. A doublemasked comparison of carteolol and timolol in ocular hypertension. Am J Ophthalmol 1988;105:150-4.
13. Stewart WC, Shields MB, Allen RC, et al. A 3-month comparison of 1% and 2% carteolol and 0.5% timolol in openangle glaucoma. Graefes Arch Clin Exp Ophthalmol 1991; 229:258-61.
14. Brazier DJ, Smith SE. Ocular and cardiovascular response to topical carteolol 2% and timolol 0.5% in healthy volunteers. Br J Ophthalmol 1988;72:101-3.
15. Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer L. Bronchial and cardiovascular effects of ocular topical β-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol. J Clin Pharmacol 1989;29:97-101.
16. van Brummelen P. The relevance of intrinsic sympathomimetic activity for ß-blocker-induced changes in plasma lipids. J Cardiovasc Pharmacol 1983;5: S51-5.
17. Leren P, Foss OP, Nordvik B, Fossbakk B. The effect of enalapril and timolol on blood lipids. Acta Med Scand 1988; 223:321-6.
18. Kochar MS, Barboriak JJ, Kalbfleisch JH. Effects of a beta blocker with intrinsic sympathomimetic activity on serum lipids. Clin Res 1983;31:196A.
19. Coleman AL, Diehl DLC, Jampel HD, Bachorik PS, Quigley HA. Topical timolol decreases plasma high-density lipoprotein cholesterol level. Arch Ophthalmol 1990;108:1260-3.
20. West J, Longstaff S. Topical timolol and serum lipoproteins. Br J Ophthalmol 1990;74:663-4.
21. Diehl DLC, Coleman AL, Jampel HD, Quigley HA. Topical timolol and serum lipoproteins. Br J Ophthalmol 1992;76: 191-2.
22. Joyce PW, Sunder Raj P. Topical beta blockers and serum lipoproteins. Br J Ophthalmol 1991;75:510-11.
23. Vogel R. Topical timolol and serum lipoproteins [Letter]. Arch Ophthalmol 1991; 109:1341.
24. Shaw BR, Weinreb RN. Topical timolol and serum lipoproteins [Letter]. Arch Ophthalmol 1991;109:1341-2.
25. Freedman SF, Freedman NJ, Shields MB, et al. Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level. Am J Ophthalmol 1993;116:600-11.
26. Stamper MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991; 325:373-81.
27. Cruickshank JM. ß-Blockers: primary and secondary prevention. J Cardiovasc Pharmacol 1992;20(suppl 11): S55-69.
28. Wilhelmsen LW. Prevention of myocardial infarction. J Hypertens 1991; 9: S3-6.
29. James IM. Pharmacologic effects of beta-blocking agents used in the management of glaucoma [Summary], Surv Ophthalmol 1989;33(suppl):453-4.
30. Pillunat L, Stodtmeister R. Effect of different anti-glaucomatous drugs on ocular perfusion pressures. J Ocul Pharmacol 1988;4:231-42.
31. Grunwald JE, Delehanty J. Effect of topical carteolol on the normal human retinal circulation. Invest Ophthalmol Vis Sci 1992;33:1853-6.
32. Pillunat LE, Stodtmeister R. Pressure compliance test of the optic nerve head: influence of different anti-glaucoma drugs [Summary]. Surv Ophthalmol 1989;33(suppl):465-6.
33. Negishi C, Kanai A, Nakajima A, Funahashi M, Kitazawa Y, Komemushi S. Effects of beta-blocking agent carteolol on healthy volunteers and glaucoma patients. Acta Soc Ophthalmol Jpn 1991;85:57-66.
34. Negishi C, Kanai A, Nakajima A, Funahashi M, Kitazawa Y. Ocular effects of beta-blocking agent carteolol on healthy volunteers and glaucoma patients. Jpn J Ophthalmol 1981; 25:464-76.
35. Berlin I, Marcel P, Uzzan B, Millon D, Le Hoang P, Puech AJ. A single dose of three different ophthalmic betablockers antagonizes the chronotropic effect of isoproterenol in healthy volunteers. Clin Pharmacol Ther 1987;41: 622-6.
36. Morita S, Akiyama H, Shirato S, Yumita A, Go F, Kitazawa Y. Ocular hypotensive effect and pharmacokinetics of carteolol. Jpn J Ophthalmol 1982;26:109-10.
37. Kitazawa Y, Azuma I, Takase M, Komemushi S. Ocular hypotensive effects of carteolol hydrochloride in primary open-angle glaucoma and ocular hypertensive patients. A double-masked cross-over study for the determination of concentrations optimal for the clinical use. Acta Soc Ophthalmol Jpn 1981;85:798-804.
38. Gorgone G, Spina F, Amantia L. Carteolol: preliminary study on ocular pressure-reducing action. Ophthalmologica Basel 1983;187:171-3.
39. Kitazawa Y, Horie T, Shirato S. Efficacy and safety of carteolol hydrochloride: a new beta-blocking agent for the treatment of glaucoma. In: Henkind P, ed. Acta: XXIV International Congress of Ophthalmology. Philadelphia: JB Lippincott, 1983:683-6.
40. Duff GR, Newcombe RG. The 12-hour control of intraocular pressure on carteolol 2% twice daily. Br J Ophthalmol 1988; 72:890-1.
41. Frishman WH, Kostis J. The significance of intrinsic sympathomimetic activity in beta-adrenoceptor blocking drugs. Cardiovascular Reviews and Reports 1982;3:503-12.